Phospholipase D activity underlies very-low-density lipoprotein (VLDL)-induced aldosterone production in adrenal glomerulosa cells

Endocrinology (United States)

Volumn 155, Issue 9, 2014, Pages 3550-3560

  Tsai, Ying Ying ^b   Rainey, William E ^b,d   Pan, Zhi Qiang ^b,e   Frohman, Michael A ^c   Choudhary, Vivek ^a,b   Bollag, Wendy B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; MESSENGER RNA; PHOSPHOLIPASE D; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2;

ADRENAL CORTEX CELL; ANIMAL CELL CULTURE; ARTICLE; BOVINAE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MUTANT; PRIMARY CULTURE; PROTEIN EXPRESSION; STEROIDOGENESIS; ZONA GLOMERULOSA; ANIMAL; CATTLE; CELL CULTURE; CELL LINE; ENZYMOLOGY; GENETICS; METABOLISM;

ALDOSTERONE; ANIMALS; CATTLE; CELL LINE; CELLS, CULTURED; HUMANS; LIPOPROTEINS, VLDL; PHOSPHOLIPASE D; ZONA GLOMERULOSA;

EID: 84907048313     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1159     Document Type: Article

References (41)

1. Brown NJ. This is not Dr. Conn's aldosterone anymore. Trans Am Clin Climatol Assoc. 2011;122:229-243.
2. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J. 1995;16(Suppl C): 45-50.
3. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldoste-rone in renal disease. Curr Opin Nephrol Hypertens. 2001;10:105-110.
4. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53-58.
5. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens. 1994;7: 886-893.
6. Kidambi S, Kotchen JM, Krishnaswami S, Grim CE, Kotchen TA. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans. Am J Hypertens. 2009;22:1303-1308.
7. Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res. 2009;32:649-657.
8. Liu Z, Li H, Li Y, et al. Up-regulation of VLDL receptor expression and its signaling pathway inducedbyVLDL and beta-VLDL. J Hua-zhong Univ Sci Technolog Med Sci. 2009;29:1-7.
9. Banfi C, Mussoni L, Risé P, et al. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res. 1999;85:208-217.
10. Sekine Y, Koike H, Nakano T, Nakajima K, Suzuki K. Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells. Clin Chim Acta. 2007;383:78-84.
11. Frontini MJ, O'Neil C, Sawyez C, Chan BM, Huff MW, Pickering JG. Lipid incorporation inhibits Src-dependent assembly of fi-bronectin and type I collagen by vascular smooth muscle cells. Circ Res. 2009;104:832-841.
12. Xing Y, Rainey WE, Apolzan JW, Francone OL, Harris RB, Bol-lag WB. Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL). Endocrinology. 2012;153: 721-731.
13. Saha S, Bornstein SR, Graessler J, Kopprasch S. Very-low-density lipoprotein mediates transcriptional regulation of aldosterone syn-thaseinhuman adrenocortical cells through multiple signaling pathways. Cell Tissue Res. 2012;348:71-80.
14. Shah BH, Baukal AJ, Shah FB, Catt KJ. Mechanisms of extracellu-larly regulated kinases 1/2 activationin adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. Mol Endocri-nol. 2005;19:2535-2548.
15. Natarajan R, Stern N, Nadler J. Diacylglycerol provides arachidonic acid for lipoxygenase products that mediate angiotensin II-induced aldosterone synthesis. Biochem Biophys Res Commun. 1988;156: 717-724.
16. Bollag WB, Barrett PQ, Isales CM, Liscovitch M, Rasmussen H. A potential role for phospholipase-D in the angiotensin-II-induced stimulation of aldosterone secretion from bovine adrenal glomeru-losa cells. Endocrinology. 1990;127:1436-1443.
17. Bollag WB, Jung E, Calle RA. Mechanism of angiotensin II-induced phospholipase D activation in bovine adrenal glomerulosa cells. Mol Cell Endocrinol. 2002;192:7-16.
18. Zheng X, Bollag WB. AngII induces transient phospholipase D activity in the H295R glomerulosa cell model. Mol Cell Endocrinol. 2003;206:113-122.
19. Parmar J, Key RE, Rainey WE. Development of an adrenocortico-tropin-responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab. 2008;93:4542-4546.
20. Wang T, Rowland JG, Parmar J, Nesterova M, Seki T, Rainey WE. Comparison of aldosterone production among human adrenocortical cell lines. Horm Metab Res. 2012;44:245-250.
21. Wang T, Rainey WE. Human adrenocortical carcinoma cell lines. Mol Cell Endocrinol. 2012;351:58-65.
22. Shapiro BA, Olala L, Arun SN, Parker PM, George MV, Bollag WB. Angiotensin II-activated protein kinase D mediates acute aldosterone secretion. Mol Cell Endocrinol. 2010;317:99-105.
23. Sung TC, Roper RL, Zhang Y, et al. Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. EMBO J. 1997;16: 4519-4530.
24. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153:1774-1782.
25. Groussin L, Massias JF, Bertagna X, Bertherat J. Loss of expression of the ubiquitous transcription factor cAMP response element-binding protein (CREB) and compensatory overexpression of the activator CREMtau in the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab. 2000;85:345-354.
26. Olala LO, Seremwe M, Tsai YY, Bollag WB. A role for phospholipase D in angiotensin II-induced protein kinase D activation in adrenal glomerulosa cell models. Mol Cell Endocrinol. 2013;366: 31-37.
27. Scott SA, Selvy PE, Buck JR, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009;5:108-117.
28. Clem BF, Hudson EA, Clark BJ. Cyclic adenosine 3', 5'-monophos-phate (cAMP) enhances cAMP-responsive element binding (CREB) protein phosphorylation and phospho-CREB interaction with the mouse steroidogenic acute regulatory protein gene promoter. Endocrinology. 2005;146:1348-1356.
29. den Hartigh LJ, Altman R, Norman JE, Rutledge JC. Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFKB. Am J Physiol Heart Circ Physiol. 2014;306:H109-H120.
30. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest. 2001;108:793-797.
31. Saha S, Graessler J, Bornstein SR, Schwarz PE, Kopprasch S. Stimulation of phagocyte adhesion to endothelial cells by modified VLDL and HDL requires scavenger receptor BI. Mol Cell Biochem. 2013;383:21-28.
32. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10:7-13.
33. Qin H, Frohman MA, Bollag WB. Phospholipase D2 mediates acute aldosterone secretion in response to angiotensin II in adrenal glomerulosa cells. Endocrinology. 2010;151:2162-2170.
34. Su W, Yeku O, Olepu S, et al. 5-Fluoro-2-indolyl des-chlorohalo-pemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009; 75:437-446.
35. Su W, Chen Q, Frohman MA. Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol. 2009;5:1477-1486.
36. Oude Weernink PA, López de Jesús M, Schmidt M. Phospholipase D signaling: orchestration by PIP2 and small GTPases. Naunyn Schmiedebergs Arch Pharmacol. 2007;374:399-411.
37. Meier RK, Clark BJ. Angiotensin II-dependent transcriptional activation of human steroidogenic acute regulatory protein gene by a 25-kDa cAMP-responsive element modulator protein isoform and Yin Yang 1. Endocrinology. 2012;153:1256-1268.
38. Manna PR, Soh JW, Stocco DM. The involvement of specific PKC isoenzymes in phorbol ester-mediated regulation of steroidogenic acute regulatory protein expression and steroid synthesis in mouse Leydig cells. Endocrinology. 2011;152:313-325.
39. Olala LO, Choudhary V, Johnson M, Bollag WB. In press Angio-tensin II-induced protein kinaseDactivates the ATF/CREB family of transcription factors and promotes StAR mRNA expression. Endocrinology, e-published ahead of print April 7, 2014.
40. Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis-a possible pathophysiological link? Horm Metab Res. 2012;44:239-244.
41. Saha S, Schwarz PE, Bergmann S, Bornstein SR, Graessler J, Ko-pprasch S. Circulating very-low-density lipoprotein from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and aldosterone synthesis. Horm Metab Res. 2013;45: 169-172.